Daxor Corporation · NASDAQ:DXR

Daxor — Investor Presentation (March 2026)

37 slides from Daxor's investor presentation, March 2026

Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channel
Slide 4: Mission and Vision
Mission Advance healthcare by enabling Vision optimal fluid Optimal blood management volume for all. with blood volume analysis. COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED. COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 5: Daxor Is the Global Leader in Blood Volume Measurement Technology
Daxor Is the Global Leader in Blood Volume Measurement Technology Daxor operates a 20,000 SF state- of-the-art R&D and production facility in Oak Ridge, TN. This vertically integrated infrastructure can produce 400+ BVA analyzers and 200,000 test kits annually. COPYRIGHT © 2026 DAXOR CORPORATION. AL
Slide 6: Daxor is a Radiopharmaceutical Company Selling Volumex Test Kits
Daxor is a Radiopharmaceutical Company Selling Volumex® Test Kits Used With Our BVA Companion Analyzer Every BVA test consumes a test kit, ensuring a predictable and scalable recurring income stream. BVA Companion Analyzer Volumex Radiopharmaceutical COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RE
Slide 7: Blood Volume Management: Cornerstone of Care for Acute and Chronic Conditions
Blood Volume Management: The Cornerstone of Care for Acute and Chronic Conditions in Both Inpatient and Outpatient Settings Examples COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 8: 134M+ Patient Market: Untapped Potential for Blood Volume Analysis
134M+ Patient Market: The Untapped Potential for Blood Volume Analysis to Improve Outcomes and Healthcare Costs Heart Failure1 ~7 million affected U.S. Healthcare Burden Hyponatremia6 Hypertension4 3 to 6 million 120 million adults affected affected Heart Failure $70 billion by Hypertension Blood Vo
Slide 9: The Heated Debate – What is the patient's volume status?
“Should we try another treatment strategy?” The Heated Debate – What is the patient’s volume status? “Her hematocrit is very “I think he’s still a bit low. But she’s been “It might be time to wet; he needs to be getting lots of fluids. It’s pivot to a new diuresed.” not true anemia, it’s treatment p
Slide 10: Optimal Blood Volume is Central to Effective Healthcare
Optimal Blood Volume is Central to Effective Healthcare Other volume assessment methods are inaccurate, costly, and invasive – often leading to suboptimal outcomes. Single Single BVA Blood BVA-100 BlooTest COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 12: Capitalizing on the Next Generation of Care
Capitalizing on the Next Generation of Care Test results achievable FDA-Cleared within 30 minutes Over 75,000+ Tests Shipped >95% Accurate Administered Direct Measurement Inpatient and at point of Total Blood Volume, outpatient of care Plasma, & Red Cell Volume Over 170+ Peer-Reviewed Studies Confir
Slide 13: Over 75,000+ Tests Shipped to Leading U.S. Institutions
Over 75,000+ Tests Shipped to Leading U.S. Institutions, Demonstrating Widespread Utilization COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 14: New Daxor BVA Analyzer FDA-Cleared August 2025
New Game-Changing Daxor BVA Analyzer FDA-Cleared August 2025 Nasdaq Closing Bell Ceremony, August 8, 2025 COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED. COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 15: A Technology Leap for Greater Patient Access
A Technology Leap for Greater Patient Access Leveraging 50 years of innovation and over 75,000 tests with our BVA-100 device, we've developed the new BVA analyzer. This faster, easier, hand-held device delivers precise blood volume data making it accessible for use across both hospital and ambulator
Slide 16: Fast. Accurate. Easy.
Fast. Accurate. Easy. Inject Volumex®, Process Samples and Get Immediate Results COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED. COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 17: ezBVA Lab Service – No Capital Investment or Lab Work
ezBVA Lab Service – No Capital Investment or Lab Work Daxor’s novel CLIA certified facility provides on-demand, next day blood volume analysis results. COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 20: BVA Redefines Outcomes in Heart Failure
BVA Redefines Outcomes in Heart Failure Study Underscores BVA’s Market Potential in Heart Failure Retrospective analysis in hospitalized heart failure patients n = 245, Mixed HFpEF/HFrEF 56% 82% 86% Reducing 30-day Reducing 30-day Reducing 1-year readmissions by mortality by 82% mortality by 86% 56%
Slide 21: BVA Drives Superior Outcomes and Value in Critical Care
BVA Drives Superior Outcomes and Value in Critical Care Every clinician understands the importance of maintaining normal blood volume, but the problem is how to measure it. The blood volume analyzer will mitigate the heated debate at the bedside. - Dr. Mihae Yu Blood Volume Measurements Improved ICU
Slide 22: Driving Exceptional Value in Healthcare
Driving Exceptional Value in Healthcare Blood Volume-Guided Treatment Extremely Cost Effectivea Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF 2.32 QALY 5X More Cost- Average Life-Extension Per Patient Effective Well above 0.227 previously reportedb Far be
Slide 24: Making a Difference in Multiple Medical Conditions
Making a Difference in Multiple Medical Conditions Patients With Critical Blood Volume Derangements in the U.S. Annually • Heart Failure: 7M patients, 11M deaths, 1M annual hospitalizations Heart Failure 7.0M • Critical Care/Sepsis: 7.4 M admissions annually Critical Care 5.7M • Broadening focus ind
Slide 25: BVA Expansion Into High-Impact Outpatient Verticals
BVA Expansion Into High-Impact Outpatient Verticals • Nephrology • Oncology Infusion Centers • Post-Surgical Follow-up Clinics • POTS & Dysautonomia Centers • Advanced Heart Failure Management Centers • Private Physician Office Labs COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 26: Vast, Untapped Market Potential
Vast, Untapped Market Potential Addressable Market – Annual Recurring Revenue (in millions) $70B Heart Failure $7,000 7M patients, 30% penetration $5,790 = 2.1M tests $6,000 $5,000 $144B Critical Care, Sepsis $4,000 7M patients, 20% penetration = 1.4M tests $3,000 $2,027 $2,000 $1,351 $219B Hyperten
Slide 27: Commercialization Channels
Commercialization Channels • Direct sales to medical centers and clinics for in/outpatient use • Sales & clinical support team of 12 • International expansion with ISO 13485 certification • Military contract awards • Partnership with MedAxiom, an ACC Company COPYRIGHT © 2026 DAXOR CORPORATION. ALL R
Slide 29: Executive Summary
Executive Summary Strong Growth & Strategic Wins Clinical New Products • Next-gen analyzer FDA 510(k) cleared, • Operating revenue increased 45% • Allina Health data showed delivering results within 30 minutes year-over-year (unaudited), significant survival benefits with • Awarded $5.6M in DoD cont
Slide 30: Managing for Growth
Managing for Growth Vertical integration of Volumex® Advancing diagnostic Applied to report Next generation device and Megatope® from & therapeutic earnings with 1934 Act in FDA-cleared Aug 2025 supplier along with Glofil® strategic alliances 2026 to enhance existing suite of diagnostics Expanding s
Slide 31: Patent, Research & Development Activity
Patent, Research & Development Activity 6 3 7 9 20,000 SF New Patents New Patents US Patents Patents Research Filed 2023 Anticipated for Awarded Pending Facility 2026 Equipped with State-of-the- Art Level 4 Clean Rooms COPYRIGHT © 2026 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 32: $7M+ Government Grants for Next-Gen Systems
$7M+ Government Grants for Next-Gen Systems • Simple, fast, hand-held blood volume analyzer 510(k)-cleared for military and civilian use • Novel patent-pending fluorescent tracer development • BVA integration into Electronic Health Records • Clinical decision support tools for fluid management in he
Slide 33: Key Metrics
Key Metrics Convert from 1940 Act to 1934 Act Reporting in Q2-26 | Publicly Traded Since 1971 Stock Symbol: DXR Exchange: Nasdaq Recent Price: $11.38 (a/o 03/6/2026) 52 Week Range: $7.10 to $14.26 Market Cap: $66.4M (a/o 03/06/2026) Shares Outstanding: 5.83M (a/o 03/06/2026) Free Float: 3.0M (a/o 03
Slide 34: Highlights
Highlights Broad and deep IP portfolio with patented 510(k) clearance for next-generation blood volume technology analyzer, results within 30 minutes Awarded new patent for blood volume guidance Over 75,000+ tests shipped with 170+ peer-reviewed technology to improve treatment & outcomes published s
Slide 35: Senior Leadership
Senior Leadership Michael Jonathan John L. Robert Kathryn A. Linda Noa Kohl, Feldschuh, Feldschuh, Jefferies, Michel, Kornafel, Cooper, MDS, MBA President & Chief Scientific MD, MBA, CPA, MBA MT (ASCP) VP Development VP Grants & Chief Executive Officer MPH, FACC, & Operations Contracts Chief Financi
Slide 36: References
References 1. Economic Issues in Heart Failure in the United States 2. Intelligent Intensive Care Unit 3. Sepsis Alliance 4. Health Care Expenditures and Use Associated with Hypertension Among U.S. Adults 5. Transfusion Transmitted Disease 6. The Prevalence of Hyponatremia in the U.S 7. American Soc

Daxor — Investor Presentation (March 2026) on 6ix

Daxor — Investor Presentation (March 2026)

Slide 1: Presentation March 2026

Slide 2: Forward-Looking Statement

Slide 3: Who We Are & Opportunity

Slide 4: Mission and Vision

Slide 5: Daxor Is the Global Leader in Blood Volume Measurement Technology

Slide 6: Daxor is a Radiopharmaceutical Company Selling Volumex Test Kits

Slide 7: Blood Volume Management: Cornerstone of Care for Acute and Chronic Conditions

Slide 8: 134M+ Patient Market: Untapped Potential for Blood Volume Analysis

Slide 9: The Heated Debate – What is the patient's volume status?

Slide 10: Optimal Blood Volume is Central to Effective Healthcare

Slide 11: Solution & Technology

Slide 12: Capitalizing on the Next Generation of Care

Slide 13: Over 75,000+ Tests Shipped to Leading U.S. Institutions

Slide 14: New Daxor BVA Analyzer FDA-Cleared August 2025

Slide 15: A Technology Leap for Greater Patient Access

Slide 16: Fast. Accurate. Easy.

Slide 17: ezBVA Lab Service – No Capital Investment or Lab Work

Slide 18: Clinical & Health Economic Benefits

Slide 19: Scientific Partnerships Fuel Our Market Leadership

Slide 20: BVA Redefines Outcomes in Heart Failure

Slide 21: BVA Drives Superior Outcomes and Value in Critical Care

Slide 22: Driving Exceptional Value in Healthcare

Slide 23: Commercial Momentum

Slide 24: Making a Difference in Multiple Medical Conditions

Slide 25: BVA Expansion Into High-Impact Outpatient Verticals

Slide 26: Vast, Untapped Market Potential

Slide 27: Commercialization Channels

Slide 28: Strategy & Conclusion

Slide 29: Executive Summary

Slide 30: Managing for Growth

Slide 31: Patent, Research & Development Activity

Slide 32: $7M+ Government Grants for Next-Gen Systems

Slide 33: Key Metrics

Slide 34: Highlights

Slide 35: Senior Leadership

Slide 36: References

Slide 37: Contact Daxor